Immutep (IMMP) Common Equity (2011 - 2026)
Immutep's (IMMP) quarterly Common Equity came in at $43.6 million in Q2 2026, down 52.55% on a YoY basis from $92.0 million in Q2 2025, and down 32.78% quarter-over-quarter from $64.9 million in Q4 2025.
Analysis
Immutep (IMMP) Common Equity (2011 - 2026) Analysis & Trends
Immutep (IMMP) has reported Common Equity for 16 consecutive years, with $43.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Common Equity fell 52.55% year-over-year to $43.6 million; the trailing twelve-month figure through Jun 2026 stood at $43.6 million (down 52.55% YoY), and the FY2026 full-year result was $43.6 million, down 52.55% from the prior year.
- Common Equity eased to $43.6 million in Q2 2026 per IMMP's latest filing, from $64.9 million in the prior quarter.
- Across five years, Common Equity topped out at $124.9 million in Q2 2024 and bottomed at $43.6 million in Q2 2026.
- Historically, Common Equity has averaged $80.3 million across 5 years, with a median of $75.3 million in 2023.
- The sharpest annual moves came in 2024 and 2026: Common Equity surged 49.82% in 2024, then tumbled 52.55% in 2026.
- Over 5 years, Common Equity stood at $50.4 million in 2022, then soared by 49.41% to $75.3 million in 2023, then jumped by 49.82% to $112.8 million in 2024, then slumped by 42.43% to $64.9 million in 2025, then slumped by 32.78% to $43.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $43.6 million, $64.9 million, and $92.0 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Immutep | 51.68 Mn | 51.68 Mn | - | 43.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 43.65 Mn |
| Dec 31, 2025 | 64.93 Mn |
| Jun 30, 2025 | 91.99 Mn |
| Dec 31, 2024 | 112.79 Mn |
| Jun 30, 2024 | 124.90 Mn |
| Dec 31, 2023 | 75.28 Mn |
| Jun 30, 2023 | 91.21 Mn |
| Dec 31, 2022 | 50.39 Mn |
| Jun 30, 2022 | 67.38 Mn |
| Dec 31, 2021 | 79.32 Mn |
| Jun 30, 2021 | 56.42 Mn |
| Dec 31, 2020 | 44.36 Mn |
| Jun 30, 2020 | 21.83 Mn |
| Dec 31, 2019 | 19.15 Mn |
| Jun 30, 2019 | 17.08 Mn |
| Jun 30, 2018 | 25.38 Mn |
| Dec 31, 2017 | 20.86 Mn |
| Jun 30, 2017 | 19.93 Mn |
| Mar 31, 2017 | 21.56 Mn |
| Dec 31, 2016 | 31.25 Mn |